cannabidiolic acid (RSBT-001) / Real Science Holdco, Synthonics - LARVOL DELTA

RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue (GlobeNewswire) - "RSBT-001 was evaluated in three separate, inducible experiments designed to test the ability of RSBT-001 to attenuate inflammation and fibrosis in human precision cut lung slices (PCLuS). RSBT-001 demonstrated a statistically significant reduction of key inflammatory biomarkers, validating results from two prior animal studies. RSBT-001 also demonstrated a statistically significant reduction in key mediators of remodeling/fibrosis, adding new, exciting properties to the RSBT-001 profile that warrant further exploration."

Preclinical • Fibrosis • Pulmonary Disease • Respiratory Diseases

Preclinical Interleukin Profile of RSBT-001: A First-in-Class, Steroid-free Immune Modulator in Development for Idiopathic Pulmonary Fibrosis (ATS 2024) - "5, 1, 5, and 10 mg/kg) as compared with two doses of dexamethasone (2. RSBT-001 offers a novel type of immune modulation that may play an important role as a future treatment option for the management of IPF. Pursuant to this, an ongoing research collaboration with the NIH will explore both a preventive and treatment paradigm in a bleomycin mouse model to further define the impact of RSBT-001 on inflammation and fibrosis."

Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immune Modulation • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Rare Diseases • Respiratory Diseases

RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine (GlobeNewswire) - "RS BioTherapeutics...announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine, one of the largest equity crowdfunding platforms in the U.S. 'The launch of this crowdfunding campaign will enable individual investors to support our efforts in developing breakthrough pharmaceutical medicines to improve the treatment and outcomes for patients suffering from respiratory diseases characterized by pulmonary inflammation,' says RS BioTherapeutics’ Chief Executive Officer, Dean Hart. 'Our first investigational compound, RSBT-001, is a first-in-class, steroid-free, multi-targeted immune modulator in development for Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF).'"

Financing • Chronic Obstructive Pulmonary Disease • Idiopathic Pulmonary Fibrosis • Pulmonary Disease

RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit (Yahoo Finance) - "RS BioTherapeutics...is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit hosted by the American Thoracic Society (ATS)....'We are excited to share the science behind our first-in-class, steroid-free agent RSBT-001 and how it can serve as a development platform for serious lung diseases characterized by pulmonary inflammation.'"

Clinical • Chronic Obstructive Pulmonary Disease • Idiopathic Pulmonary Fibrosis • Pulmonary Disease

RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance on Development of First-in-Class Agent Focused on Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis (Yahoo Finance UK) - "RS BioTherapeutics...is pleased to announce the formation of its Therapeutic Expert Council (TEC). The TEC will help guide the development of RS BioTherapeutics’ first-in-class, steroid-free agent, RSBT-001, in development for Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death in the world; and Idiopathic Pulmonary Fibrosis (IPF), a rare disease with no cure that claims 40,000 lives each year in the U.S."

Clinical • Chronic Obstructive Pulmonary Disease • Idiopathic Pulmonary Fibrosis • Pulmonary Disease

RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis (Yahoo Finance) - "RS BioTherapeutics...has entered into a Research Collaboration Agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), an institute within the National Institutes of Health (NIH), to assess the anti-inflammatory and anti-fibrotic potential of RS BioTherapeutics’ lead compound, RSBT-001, in a preclinical pulmonary fibrosis model."

Licensing / partnership • Idiopathic Pulmonary Fibrosis • Pulmonary Disease • Respiratory Diseases

RS BioTherapeutics Selects Recipharm as Product Characterization Partner (GlobeNewswire) - "RS BioTherapeutics....is pleased to announce that is has selected Recipharm, a leading Contract Development and Manufacturing Organization (CDMO), as its partner to conduct product characterization for its investigational compound, RSBT-001. Product characterization is an important next step for RSBT-001 before filing an Investigational New Drug (IND) application with the FDA for the treatment of chronic obstructive pulmonary disease (COPD)."

Licensing / partnership • Chronic Obstructive Pulmonary Disease • Respiratory Diseases

RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound (GlobeNewswire) - "RS BioTherapeutics...is pleased to announce that is has entered into a license agreement with Synthonics, Inc. for the exclusive, worldwide right to use Synthonics’ metal coordinated cannabinoid in nebulized form for the treatment of pulmonary inflammatory disorders. RS BioTherapeutics is developing its lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD)....Various sources estimate the global pulmonary drug delivery systems market was approximately $51 billion in 2021, and it is expected to be worth around $92 billion by 2030, with a compound annual growth rate of 6.6 percent within in next 10 years."

Licensing / partnership • Chronic Obstructive Pulmonary Disease • Respiratory Diseases